Also found in: Medical.
CALGBCancer and Leukemia Group B
References in periodicals archive ?
Two large randomized phase III studies, SWOG S0033/ CALGB 150105 (8) and 62005, (9) carried out in the United States and Canada, and Europe and Australasia, respectively, assessed the efficacy of standard-dose imatinib (400 mg daily) and high-dose imatinib (400 mg twice daily) in patients with metastatic or unresectable GIST.
2] Nonstandard abbreviations: IOM, Institute of Medicine; NCI, National Cancer Institute; FDA, US Food and Drug Administration; CALGB, Cancer and Leukemia Group B; CTEP, Cancer Therapy Evaluation Program; IDE, investigational device exemption; IVDMIA, in vitro diagnostic multivariate index assay; IRB, institutional review board; GEO, Gene Expression Omnibus; MIAME, Minimum Information about a Microarray Experiment.
Meyerhardt and his group published an analysis of data from a National Cancer Institute-sponsored study called CALGB 89803 that involved 1,264 patients with stage II colon cancer, randomized to treatment with 5-fluorouracil and leucovorin with or without irinotecan following surgical resection.
cyclophosphamide-epirubicin-fluorouracil)] and CALGB 8541 trials all demonstrated anthracycline sensitivity in HER2-amplified tumours.
The phase III CALGB 80405 trial in which patients are randomized to FOLFIRI/FOLFOX plus cetuximab or bevacizumab or cetuximab and bevacizumab [63] will hopefully answer this question and establish which targeted agent is the preferred combination partner.
The practice is affiliated with national Clinical Study protocol groups, CALGB,(Cancer and Leukemia Group B), and NSABP(National Surgical Adjuvant Breast and Bowel Project), offering patients the opportunity of national clinical studies, through The Vermont Regional Cancer Center.
The first of the studies, CALGB 8541, began accruing patients 20 years ago.
CALGB 9380: a prospective trial of the feasibility of thoracoscopy/laparoscopy in staging esophageal cancer.
10,11,17) The CALGB study (22) found that treatment with high-dose cytarabine has a better outcome than treatment with intermediate- or low-dose cytarabine.
Much impetus derived from a study of 85 women within Cancer and Leukemia Group B (CALGB) involving the use of high-dose cyclophosphamide, cisplatinum, and carmustine [Solid Tumor Autologous Marrow Transplant Program (STAMP) I regimen] as consolidation after an intensive regimen of cyclophosphamide, doxorubicin, and 5-fluorouracil in CALGB 8782 (69,70).
Commonly used regimens for adults with ALL stem from a series of clinical trials conducted by The Cancer and Leukemia Group B (CALGB), including the CALGB 8811 (Larson) regimen that used a five-drug regimen for induction therapy.
However, first-line EGFR inhibitor prescribing is expected to increase due to the data from the CALGB 80405, FIRE-3 and PEAK trials showing a survival benefit for EGFR inhibitors in wild-type RAS patients.